Edgewise Therapeutics

General Information
Our vision is to improve the lives of patients and families suffering from rare muscle disorders, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), by building the world’s leading muscle-focused, precision medicine company. In less than four years, we have matured into a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing drugs to treat patients with rare muscular disorders for which there is significant unmet medical need. 
Our lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). This drug candidate, EDG-556, is currently in a Phase 1 clinical trial.
(Note: Edgewise Therapeutics upsized its IPO at pricing on March 25, 2021, by pricing 11 million shares, up from 10 million in the prospectus, at $16 – the top of its $14-to-$16 range – to raise $176 million.)
Industry: Pharmaceuticals
Employees: 19
Founded: 2017
Contact Information
Address 3415 Colorado Ave. Boulder, CO 80303
Phone Number (303) 735-8373
Web Address http://www.edgewisetx.com
View Prospectus: Edgewise Therapeutics
Financial Information
Market Cap $548.55mil
Revenues $0 mil (last 12 months)
Net Income $-17.12 mil (last 12 months)
IPO Profile
Symbol EWTX
Exchange NASDAQ
Shares (millions): 11.0
Price range $16.00 - $16.00
Est. $ Volume $176.0 mil
Manager / Joint Managers J.P. Morgan/ Goldman Sachs/ SVB Leerink
CO-Managers Wedbush Securities
Expected To Trade: 3/26/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change